Journal
MOLECULAR CELL
Volume 82, Issue 16, Pages 3030-+Publisher
CELL PRESS
DOI: 10.1016/j.molcel.2022.06.003
Keywords
-
Categories
Funding
- Cancer Prevention and Research Institute of Texas (CPRIT) [RR190058]
- Department of De- fense Kidney Cancer Research Program Idea Development Award [W81XWH1910813]
- National Cancer Institute [R01CA211732, P50CA196516]
- NCI [R37CA226771]
- Welch Foundation Award [I-1879]
- UT Presidential Scholar Award
- National Cancer Insti- tute [P30 CA142543]
- CPRIT [RP180770]
- U.S. Department of Defense (DOD) [W81XWH1910813] Funding Source: U.S. Department of Defense (DOD)
Ask authors/readers for more resources
The JMJD6-DGAT1 axis plays a critical role in ccRCC tumor development. JMJD6 interacts with RBM39 and co-occupies the DGAT1 gene promoter to induce DGAT1 expression. Silencing JMJD6 reduces DGAT1 expression, leading to inhibition of lipid droplet formation and tumorigenesis. Pharmacological inhibition of DGAT1 suppresses lipid droplet formation and ccRCC tumorigenesis.
Characterized by intracellular lipid droplet accumulation, clear cell renal cell carcinoma (ccRCC) is resistant to cytotoxic chemotherapy and is a lethal disease. Through an unbiased siRNA screen of 2-oxoglutarate (2-OG)-dependent enzymes, which play a critical role in tumorigenesis, we identified Jumonji domain -contain-ing 6 (JMJD6) as an essential gene for ccRCC tumor development. The downregulation of JMJD6 abolished ccRCC colony formation in vitro and inhibited orthotopic tumor growth in vivo. Integrated ChIP-seq and RNA-seq analyses uncovered diacylglycerol O-acyltransferase 1 (DGAT1) as a critical JMJD6 effector. Mechanis-tically, JMJD6 interacted with RBM39 and co-occupied DGAT1 gene promoter with H3K4me3 to induce DGAT1 expression. JMJD6 silencing reduced DGAT1, leading to decreased lipid droplet formation and tumorigenesis. The pharmacological inhibition (or depletion) of DGAT1 inhibited lipid droplet formation in vitro and ccRCC tumorigenesis in vivo. Thus, the JMJD6-DGAT1 axis represents a potential new therapeu-tic target for ccRCC.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available